105 related articles for article (PubMed ID: 20065180)
1. Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies.
Arena V; Pennacchia I; Monego G; Carbone A; Capelli A
J Clin Oncol; 2010 Feb; 28(5):e83-4; author reply e85-8. PubMed ID: 20065180
[No Abstract] [Full Text] [Related]
2. How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
Schmidt C
J Natl Cancer Inst; 2011 Jan; 103(2):87-9. PubMed ID: 21191114
[No Abstract] [Full Text] [Related]
3. ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer.
Jensen JD; Knoop A; Ewertz M; Laenkholm AV
Breast Cancer Res Treat; 2012 Apr; 132(2):511-21. PubMed ID: 21667123
[TBL] [Abstract][Full Text] [Related]
4. Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis.
Van Belle V; Van Calster B; Brouckaert O; Vanden Bempt I; Pintens S; Harvey V; Murray P; Naume B; Wiedswang G; Paridaens R; Moerman P; Amant F; Leunen K; Smeets A; Drijkoningen M; Wildiers H; Christiaens MR; Vergote I; Van Huffel S; Neven P
J Clin Oncol; 2010 Sep; 28(27):4129-34. PubMed ID: 20713855
[TBL] [Abstract][Full Text] [Related]
5. Current status of HER2 testing: caught between a rock and a hard place.
Schnitt SJ; Jacobs TW
Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
[No Abstract] [Full Text] [Related]
6. Justification of the change from 10% to 30% for the immunohistochemical HER2 Scoring criterion in breast cancer.
Liu YH; Xu FP; Rao JY; Zhuang HG; Luo XL; Li L; Luo DL; Zhang F; Xu J
Am J Clin Pathol; 2009 Jul; 132(1):74-9. PubMed ID: 19864236
[TBL] [Abstract][Full Text] [Related]
7. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS
Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
[TBL] [Abstract][Full Text] [Related]
8. Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.
Tse CH; Hwang HC; Goldstein LC; Kandalaft PL; Wiley JC; Kussick SJ; Gown AM
J Clin Oncol; 2011 Nov; 29(31):4168-74. PubMed ID: 21947821
[TBL] [Abstract][Full Text] [Related]
9. Re: How do you tell whether a breast cancer is HER2 positive? Ongoing studies keep debate in high gear.
Moelans CB; van Diest PJ
J Natl Cancer Inst; 2011 Apr; 103(8):698-9. PubMed ID: 21406657
[No Abstract] [Full Text] [Related]
10. Testing for HER2 in breast cancer.
Lewis F; Jackson P; Lane S; Coast G; Hanby AM
Histopathology; 2004 Sep; 45(3):207-17. PubMed ID: 15330798
[TBL] [Abstract][Full Text] [Related]
11. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing.
Hwang CC; Pintye M; Chang LC; Chen HY; Yeh KY; Chein HP; Lee N; Chen JR
Histopathology; 2011 Nov; 59(5):984-92. PubMed ID: 22092410
[TBL] [Abstract][Full Text] [Related]
12. The importance of accuracy in HER2 testing.
Gonzalez-Angulo AM
Clin Adv Hematol Oncol; 2012 Aug; 10(8):529-31. PubMed ID: 23073051
[No Abstract] [Full Text] [Related]
13. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
14. Human epidermal growth factor receptor 2 testing in breast cancer.
Vang Nielsen K; Jørgensen JT; Schønau A; Øster A
J Clin Oncol; 2007 Sep; 25(25):4020; author reply 4021-3. PubMed ID: 17761991
[No Abstract] [Full Text] [Related]
15. The effect of delay in fixation on HER2 expression in invasive carcinoma of the breast assessed with immunohistochemistry and in situ hybridisation.
Lee AH; Key HP; Bell JA; Kumah P; Hodi Z; Ellis IO
J Clin Pathol; 2014 Jul; 67(7):573-5. PubMed ID: 24737400
[TBL] [Abstract][Full Text] [Related]
16. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines.
Hicks DG; Tubbs RR
Hum Pathol; 2005 Mar; 36(3):250-61. PubMed ID: 15791569
[TBL] [Abstract][Full Text] [Related]
19. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L
Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693
[No Abstract] [Full Text] [Related]
20. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
